Structural Heart Devices Market Size, Share & Trends Analysis by Product (Heart Valve Devices [TAVI, TMVR, TTVR], Annuloplasty Rings, Occluders and Closure Devices, Others), Indication (Valvular Heart Disease, Cardiomyopathy, Congenital Heart Defects, Others), End User, and Geography — Global Opportunity Analysis and Industry Forecast (2026–2036)

Market Overview

The global structural heart devices market is valued at USD 16.7 billion in 2026. This market is expected to reach USD 48.2 billion by 2036, growing at a CAGR of 11.2% during the forecast period 2026–2036.

Key Highlights

• The global structural heart devices market is projected to reach USD 48.2 billion by 2036.
• The market is expected to grow at a CAGR of 11.2% during the forecast period 2026–2036.
• The global structural heart devices market is estimated at USD 16.7 billion in 2026.
• TAVR/TAVI remains the largest product segment, accounting for around 50% of total market revenue in 2026.
• North America is expected to dominate the market with the largest share in 2026, supported by high clinical adoption and favorable reimbursement policies.
• Asia-Pacific is projected to witness the fastest growth during the forecast period, fueled by a rising geriatric population and improving healthcare access.
• LAA closure devices are identified as one of the fastest-growing sub-segments, driven by the increasing incidence of atrial fibrillation.
• Valvular heart disease affects approximately 13% of individuals aged 75 and older, providing a strong long-term driver for the market.

Market Insights
                                                                                                       Click here to: Get Free Sample Pages of this Report

The global structural heart devices market is a cornerstone of the modern cardiovascular medical technology industry, focusing on the development and deployment of innovative devices to treat defects and abnormalities in the heart's valves and chambers. This market covers a wide range of life-saving technologies, including transcatheter heart valves, annuloplasty rings, and septal occluders. The primary focus is on addressing conditions such as aortic stenosis, mitral regurgitation, and congenital heart defects through minimally invasive or percutaneous approaches. The growth of this market is mainly driven by the global aging population, the increasing prevalence of valvular heart disease, and the clinical shift from high-risk open-heart surgery toward safer, transcatheter-based therapies.

Transcatheter Aortic Valve Replacement (TAVR) remains the dominant segment of the structural heart devices market and has transformed the treatment paradigm for severe aortic stenosis. Following the expansion of regulatory approvals to include low-risk patients, TAVR adoption has continued to increase and has become the predominant valve replacement approach among eligible patient populations in major markets such as the United States. Looking ahead, transcatheter mitral valve repair/replacement (TMVR) and transcatheter tricuspid valve repair/replacement (TTVR) are expected to represent the next major growth opportunities within the structural heart landscape, supported by ongoing clinical innovation and expanding product pipelines. Market demand is further reinforced by the rising prevalence of valvular heart disease in aging populations. Recent studies indicate that the prevalence of moderate or greater valvular heart disease reaches approximately 10.5% among individuals aged 75–79 years and 14.7% among those aged 80–85 years, underscoring the growing need for effective structural heart interventions.

Despite the rapid technological advancements, the structural heart devices market faces restraints, including the high cost of transcatheter procedures and the stringent regulatory pathways required for new device clearances. The financial burden on healthcare systems for these high-value devices can be a barrier to adoption in price-sensitive regions. Additionally, while minimally invasive, these procedures still carry risks of conduction disturbances and paravalvular leaks, necessitating continuous refinement in device design and delivery systems. However, the emergence of Left Atrial Appendage (LAA) closure devices as an alternative to long-term anticoagulation for stroke prevention in atrial fibrillation patients presents a substantial growth opportunity, with this segment projected to witness some of the highest growth rates in the industry.

Market Dynamics

Drivers

The major driver for the structural heart devices market is the aging global population and the subsequent increase in the prevalence of age-related heart conditions. Aortic stenosis and mitral regurgitation are significantly more common in older adults, necessitating the use of structural heart devices for repair or replacement. The American Heart Association (AHA) has highlighted that as the global population continues to age, the burden of valvular heart disease will grow, creating a sustained demand for innovative interventional therapies.

Another key driver is the expansion of clinical indications for transcatheter aortic valve replacement (TAVR). Initially reserved for high-risk surgical patients, TAVR is now increasingly being used for intermediate and low-risk patients based on robust clinical trial data demonstrating its safety and efficacy. This expansion has significantly increased the target patient population for structural heart devices. Furthermore, the continuous improvement in device delivery systems, which are becoming smaller and more flexible, is allowing for safer procedures and broader clinical adoption.

Restraints

A major restraint is the high cost of structural heart procedures and the associated devices. Transcatheter valves and closure devices are among the most expensive medical technologies, and the total cost of the procedure, including hospitalization and specialized imaging, can be a significant burden on healthcare budgets. In many emerging markets, the lack of adequate reimbursement and the high out-of-pocket costs for patients can limit the adoption of these life-saving technologies. Furthermore, the risk of complications such as stroke or conduction disturbances requiring permanent pacemaker implantation remains a concern for both clinicians and patients.

Opportunities

The development of transcatheter therapies for the mitral and tricuspid valves (TMVR and TTVR) presents a massive growth opportunity. While TAVR is a mature segment, the mitral and tricuspid markets are in the early stages of development and offer significant untapped potential. Additionally, the growth of Left Atrial Appendage (LAA) closure devices as an alternative to long-term oral anticoagulation for stroke prevention in AFib patients is a key opportunity. As more patients seek alternatives to blood thinners, the demand for LAA closure devices is expected to rise sharply.

Challenges

Navigating the stringent regulatory pathways for new structural heart technologies remains a critical challenge. Manufacturers must provide extensive clinical data to demonstrate long-term safety and durability, which can be a costly and time-consuming process. Furthermore, the shortage of highly trained interventional cardiologists and specialized heart teams in certain regions can limit the availability of structural heart procedures. Ensuring the long-term durability of bio-prosthetic valves compared to mechanical valves also remains a long-term clinical challenge for the industry.

Key Trends

Shift Toward Minimally Invasive Transcatheter Therapies

Transcatheter therapies are rapidly replacing traditional open-heart surgery across multiple structural heart indications due to their association with shorter hospital stays, faster recovery, and reduced procedural burden. The transition is most evident in aortic stenosis, where data from the Society of Thoracic Surgeons (STS) and American College of Cardiology (ACC) Transcatheter Valve Therapy Registry show that TAVR procedures in the U.S. surpassed all surgical aortic valve replacements in 2019 (72,991 vs. 57,626 procedures), marking a major shift toward catheter-based treatment. The trend has been further accelerated by the FDA's 2019 approval of TAVR for low-surgical-risk patients, expanding eligibility beyond high- and intermediate-risk populations. As clinical evidence continues to support transcatheter approaches, adoption of TAVR, TMVR, TTVR, and percutaneous closure devices is expected to increase globally.

Integration of Advanced Imaging and Digital Guidance

Advanced imaging has become a critical component of structural heart interventions, improving procedural planning, device sizing, and intraoperative guidance. Professional recommendations from the American Society of Echocardiography identify three-dimensional transesophageal echocardiography (3D TEE) and multidetector computed tomography (MDCT) as essential imaging modalities for transcatheter valve and structural heart procedures. The growing use of image fusion, real-time procedural navigation, and digital guidance platforms is enhancing procedural precision while reducing complications associated with complex interventions. As TMVR and TTVR procedures become more technically demanding than TAVR, reliance on sophisticated imaging and digital guidance technologies is expected to increase substantially.

Segment Insights

By Product: Heart Valve Devices to Hold Largest Share

Based on product, the overall structural heart devices market is segmented into Heart Valve Devices, Annuloplasty Rings, Occluders and Closure Devices, and others. In 2026, the heart valve devices segment is expected to hold the largest share of the market. This dominance is due to the established clinical success of TAVR and the high unit cost of transcatheter valves. Heart valve devices are the primary revenue generator for major players in the structural heart market, driven by the high volume of aortic valve replacement procedures.

The occluders and closure devices market is projected to register a significant CAGR during the forecast period. This growth is driven by the rapid expansion of the LAA closure market and the increasing use of septal occluders for treating congenital heart defects like patent foramen ovale (PFO) and atrial septal defect (ASD). The shift away from long-term blood thinners is a major driver for this segment.

Geographic Insights

North America is expected to dominate the global structural heart devices market in 2026, primarily due to its advanced healthcare infrastructure, high clinical adoption of new technologies, and favorable reimbursement policies. The U.S. is the leading market for structural heart innovation, with a robust ecosystem of technology providers and research institutions. The presence of major industry players like Edwards Lifesciences and Abbott is a key driver. The key companies operating in the North American market are Edwards Lifesciences, Medtronic, Abbott, and Boston Scientific.

The Asia-Pacific structural heart devices market is projected to witness the fastest growth during the forecast period. This is driven by rapid digitalization in healthcare, increasing investments in medical technology in China and India, and a rising geriatric population. The region's large population and the increasing adoption of advanced medical technologies are driving the demand for scalable structural heart solutions. The key companies operating in the Asia-Pacific market are Terumo, Lepu Medical, Microport, and various emerging medical technology specialists in the region.

Competitive Landscape and Key Players

The global structural heart devices market is characterized by intense competition and a high degree of innovation. The competitive landscape is dominated by a few major medical device giants who have secured early regulatory approvals and are leveraging their extensive distribution networks to drive adoption. Edwards Lifesciences, Medtronic, and Abbott currently lead the market, having pioneered the TAVR and transcatheter mitral repair segments. These companies are actively investing in clinical trials to expand the indications for their devices and are acquiring specialized startups to bolster their technology portfolios.

In addition to the large incumbents, the market features several specialized companies focused on next-generation structural heart technologies, particularly for the mitral and tricuspid valves. The competitive landscape is also shaped by strategic partnerships between device manufacturers and imaging system providers. As the market evolves, the focus is shifting toward providing complete procedural solutions, including pre-procedural planning software and post-procedural monitoring. Key players in the global structural heart devices market include Edwards Lifesciences Corporation, Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Johnson & Johnson, and Terumo Corporation.

Key Questions Answered